Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FBD Biologics is developing multi-targeting immuno-oncology therapeutics using its proprietary FBDB™ platform. Its lead programs are in early clinical development for advanced solid tumors, with at least two assets having reached Phase 1 or Phase 1/2 trials. The company has demonstrated proof-of-concept data in animal models and is collaborating with Henlius to accelerate the development of novel cancer immunotherapies targeting tumors resistant to current anti-PD-(L)1 therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FBD Biologics Limited.